Clinical and immunological benefits of convalescent plasma therapy in severe COVID-19: insights from a single center open label randomised control trial
Yogiraj Ray, Shekhar Ranjan Paul, Purbita Bandopadhyay, Ranit D’rozario, Jafar Sarif, Abhishake Lahiri, Debaleena Bhowmik, Janani Srinivasa Vasudevan, Ranjeet Maurya, Akshay Kanakan, Sachin Sharma, Manish Kumar, Praveen Singh, Rammohan Roy, Kausik Chaudhury, Rajsekhar Maiti, Saugata Bagchi, Ayan Maiti, Md. Masoom Perwez, Abhinandan Mondal, Avinash Tewari, Samik Mandal, Arpan Roy, Moumita Saha, Durba Biswas, Chikam Maiti, Sayantan Chakraborty, Biswanath Sharma Sarkar, Anima Haldar, Bibhuti Saha, Shantanu Sengupta, Rajesh Pandey, Shilpak Chatterjee, Prasun Bhattacharya, Sandip Paul, Dipyaman Ganguly
doi:10.1101/2020.11.25.20237883
A single center open label phase II randomised control trial was done to assess the pathogen and host-intrinsic factors influencing clinical and immunological benefits of passive immunization using convalescent plasma therapy (CPT), in addition to standard of care (SOC) therapy in severe COVID-19 patients, as compared to patients only on SOC therapy.
Methods: Convalescent plasma was collected from patients recovered from COVID-19 following a screening protocol which also included measuring plasma anti SARS-CoV2 spike IgG content. Retrospectively, neutralizing antibody content was measured and proteome was characterized by LC-MS/MS for all convalescent plasma units that were transfused to patients. Severe COVID-19 patients with evidence for acute respiratory distress syndrome (ARDS) with PaO2/FiO2 ratio 100-300 (moderate ARDS) were recruited and randomised into two parallel arms of SOC and CPT, N=40 in each arm. Peripheral blood samples were collected on the day of enrolment (T1) followed by day3/4 (T2) and day 7 (T3). RT-PCR and sequencing was done for SARS-CoV2 RNA isolated from nasopharyngeal swabs collected at T1. A panel of cytokines and neutralizing antibody content were measured in plasma at all three timepoints. Patients were followed up for 30 days post-admission to assess the primary outcomes of all cause mortality and immunological correlates for clinical benefits.
Results: While across all age-groups no statistically significant clinical benefit was registered for patients in the CPT arm, significant immediate mitigation of hypoxia, reduction in hospital stay as well as survival benefit was recorded in severe COVID-19 patients with ARDS aged less than 67 years receiving convalescent plasma therapy. In addition to its neutralizing antibody content a prominent effect of convalescent plasma on attenuation of systemic cytokine levels possibly contributed to its benefits.
Conclusion: Precise targeting of severe COVID-19 patients is necessary for reaping the clinical benefits of convalescent plasma therapy.
Competing interests The authors declare no competing interests.
References
Agarwal, Mukherjee, Kumar, Chatterjee, Bhatnagar et al., Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial), BMJ,
doi:10.1136/bmj.m3939Arunachalam, Wimmers, Mok, Perera, Scott et al., Systems biological assessment of immunity to mild versus COVID-19 infection in humans, Science
Bandopadhyay, D'rozario, Lahiri, Sarif, Ray et al., Nature and dimensions of the cytokine storm and its attenuation by convalescent plasma in severe COVID-19, medRxiv,
doi:10.1101/2020.09.21.20199109Billett, Reyes-Gil, Szymanski, Ikemura, Stahl et al., Anticoagulation in COVID-19: Effect of Enoxaparin, Heparin, and Apixaban on Mortality, Thromb Haemost,
doi:10.1055/s-0040-1720978Edgar, MUSCLE: multiple sequence alignment with high accuracy and high throughput, Nucleic Acids Res
Goldman, Lye, Hui, Marks, Bruno et al., Remdesivir for 5 or 10 Days in Patients with Severe Covid-19, N. Engl. J. Med,
doi:10.1056/NEJMoa2015301Gu, Tyagi, Jain, Gu, Lee et al., Thrombocytopathy and endotheliopathy: crucial contributors to COVID-19 thromboinflammation, Nat Rev Cardiol
Horby, Lim, Emberson, Mafham, Bell et al., Dexamethasone in Hospitalized Patients with Covid-19 -Preliminary Report, N. Engl. J. Med,
doi:10.1056/NEJMoa2021436Huang, Wang, Li, Ren, Zhao et al., Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China, Lancet
Joyner, Senefeld, Klassen, Mills, Johnson et al., Effect of Convalescent Plasma on Mortality among Hospitalized with COVID-19: Initial Three-Month Experience, medRxiv,
doi:10.1101/2020.08.12.20169359Laing, Lorenc, Del Barrio, Das, Fish et al., A dynamic COVID-19 immune signature includes associations with poor prognosis, Nat. Med
Li, Minimap2: pairwise alignment for nucleotide sequences, Bioinformatics
Li, Zhang, Hu, Tong, Zheng et al., Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19: A Randomized Clinical Trial, JAMA
Lim, Bae, Kwon, Nauck, COVID-19 and diabetes mellitus: from pathophysiology to clinical management, Nat Rev Endocrinol,
doi:10.1038/s41574-020-00435-4Liu, Lin, Baine, Wajnberg, Gumprecht et al., Convalescent plasma treatment of severe COVID-19: a propensity score-matched control study, Nat Med,
doi:10.1038/s41591-020-1088-9Loman, Quick, Simpson, A complete bacterial genome assembled de novo using only nanopore sequencing data, Nat Methods
Lucas, Wong, Klein, Castro, Silva et al., Longitudinal analyses reveal immunological misfiring in severe COVID-19, Nature
Okonechnikov, Golosova, Fursov, Unipro UGENE: a unified bioinformatics toolkit, Bioinformatics
Rambaut, FigTree v1.4.0
Rubin, Testing an Old Therapy Against a New Disease: Convalescent Plasma for COVID-19, JAMA
Tan, Chia, Qin, Liu, Chen et al., WHO Working Group on the Clinical Characterisation and Management of COVID-19 infection. (2020) A minimal common outcome measure set for COVID-19 clinical research, Lancet Infect. Dis
